625P - Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data

K Yamaguchi,S Hironaka,N Sugimoto,T Moriwaki,Y Komatsu,T Nishina,A Tsuji,T.E Nakajima,M Gotoh,N Machida,N Fuse,T Esaki,Y Emi,Y Takinishi,S Matsumoto,N Boku,H Baba,I Hyodo

doi:10.1093/annonc/mdu334.10

625P - Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data

K Yamaguchi, S Hironaka + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdu334.10

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2014
Citations: 1	License type: publisher-specific-oa

Affiliation: Saitama Cancer Center, Chiba Cancer Center, Osaka Medical Center for Cancer and Cardiovascular Diseases, University of Tsukuba, Hokkaido University Hospital, Shikoku Cancer Center, Kobe City Medical Center General Hospital, St. Marianna University School of Medicine, Osaka Medical and Pharmaceutical University, Shizuoka Cancer Center, National Cancer Center Hospital East, National Hospital Organization Kyushu Cancer Center, Saiseikai Fukuoka General Hospital, Showa University Northern Yokohama Hospital, Kyoto University, Kumamoto University

#Yakult Honsha #S-1 Plus Cisplatin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

625P - Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.